Summit Therapeutics Inc.
SMMT•NASDAQ•Healthcare•Biotechnology

About Summit Therapeutics

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida.

Company Information

SectorHealthcare
IndustryBiotechnology
CEORobert W. Duggan
Founded2003
Employees159
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock

Contact Information

Websitewww.smmttx.com
Phone305 203 2034
Address
601 Brickell Key Drive, Suite 1000 Miami, Florida 33131 United States

Corporate Identifiers

CIK0001599298
CUSIP86627T108
ISINUS86627T1088
EIN37-1979717
SIC2834

Leadership Team & Key Executives

Dr. Mahkam Zanganeh D.D.S., M.B.A.
Co-Chief Executive Officer, President and Director
Robert W. Duggan
Co-Chief Executive Officer and Executive Chairman
Manmeet Singh Soni CPA
Chief Operating Officer, Chief Financial Officer and Director
Prof. Dame Kay Davies DBE, FRS CBE
Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor
Bhaskar Anand
Chief Accounting Officer
Nathan LiaBraaten
Senior Director of Investor Relations
Dave Gancarz
Chief Business and Strategy Officer
Dr. Fong Clow
Chief Biometrics Officer
Dr. Urte Gayko Ph.D.
Chief Regulatory, Quality and Pharmacovigilance Officer
Dr. Allen S. Yang M.D., Ph.D.
Head of Research & Development Strategy